CD303 is another specific surface marker of human pDCs, centrally involved in antigen presentation and immune tolerance. Monoclonal antibodies directed against CD303 have been studied in preclinical models and have achieved disease control in …

2013年7月11日 · Montes-Moreno et al recently reported the usefulness of SPIB as a novel immunohistochemical marker for supporting the diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN). 1 The article highlights the well-recognized difficulty in approaching the diagnosis of BPDCN, in which transformed plasmacytoid dendritic cells (PDCs) frequently...

The CD303 (BDCA-2) antigen is a novel type II transmembrane C-type lectin. 3 Remarkably, plasmacytoid dendritic cells can take up ligands via CD303 (BDCA-2), then process and present the ligands to T cells. 1,3 Unlike binding of antibodies to CD304 (BDCA-4), binding of antibodies to CD303 (BDCA-2) inhibits type I IFN production, which is ...

CLEC4C is a membrane protein of plasmacytoid dendritic cells used as a marker for this kind of cells and denoted as CD303 in the nomenclature of the Cluster of differentiation. [1]

CD303 (BDCA-2) is a highly specific marker for normal and neoplastic plasmacytoid dendritic cells and may be useful as a specific marker for the diagnosis of blastic plasmacytoid dendritic cell neoplasm.

In this study, a glyco-engineered anti-CD303 antibody (ch122A2 mAb) has been generated and further characterized. In vitro and in vivo studies demonstrate its ability to efficiently deplete human pDCs cells and inhibit IFN-α secretion.

CD303 (BDCA-2) is a type II c-type lectin specifically expressed by human PDC. CD303 signaling induces tyrosine phosphorylation and Src kinase dependent calcium influx. Cross-linking CD303 results in the inhibition of IFN-I production in stimulated PDC.

CD303 (BDCA-2) is a type II c-type lectin specifically expressed by human PDC. CD303 signaling induces tyrosine phosphorylation and Src kinase dependent calcium influx. Cross-linking CD303 results in the inhibition of IFN-I production in stimulated PDC.

We are proposing here, as a new targeted-based therapy, a novel chimeric monoclonal antibody (mAb) that mediates a strong cellular cytotoxicity directed against a specific human pDC marker, CD303.

CD303 (BDCA-2) is a highly specific marker for normal and neoplastic plasmacytoid dendritic cells and may be useful as a specific marker for the diagnosis of blastic plasmacytoid dendritic cell neoplasm.